Innate Pharma and Sobi entered a licensing partnership for lacutamab in cutaneous T-cell lymphoma (CTCL). Sobi will pay $75 million at closing, with up to $40 million in near-term Sézary syndrome milestones and up…
Aureka Biotechnologies closed a $100 million Series B to expand biological foundation models, closed-loop automated experimentation and antibody-drug discovery. Granite Asia funded the first tranche; an unnamed strategic investor led a later tranche, with…
Innovent Biologics and Daiichi Sankyo entered an exclusive agreement for commercialization of VANFLYTA (quizartinib) in China. Innovent will hold sole commercialization rights and lead market promotion, while Daiichi Sankyo retains development, manufacturing and supply…
Attovia Therapeutics priced an upsized initial public offering of 17 million shares at $17 per share, the top of its marketed range, for expected gross proceeds of $289 million before underwriting discounts and expenses….
Expedition Therapeutics closed an oversubscribed $115 million Series B led by General Atlantic, with RA Capital, Vivo Capital and all existing investors participating. The company simultaneously disclosed first-patient dosing in its global Phase 2…
Lisata Therapeutics terminated its planned merger with Kuva Labs, filed suit alleging breach of the agreement, and implemented a reduction in force affecting approximately 72% of full-time employees. The company is seeking damages and…
Pathos AI licensed ex-China rights to Alphamab Oncology’s clinical-stage TROP2/HER3 bispecific antibody-drug conjugate JSKN016 for $125 million upfront, up to $2.093 billion in milestones and high-single-digit to low-double-digit royalties. Alphamab also received a warrant…
Curium US Holdings agreed to acquire Lantheus for $102.50 per share in cash at closing plus non-transferable contingent value rights worth up to $12.00 per share. The maximum consideration is $114.50 per share and…
Supernus Pharmaceuticals and Indivior Pharmaceuticals have entered a definitive all-stock merger agreement to form a diversified central-nervous-system company with approximately $2.2 billion in combined annual revenue. Indivior shareholders are expected to own 56.5% of…
Apnimed priced an upsized initial public offering of 12.0 million common shares at $16.00 per share, generating expected gross proceeds of $192 million before underwriting discounts, commissions, and offering expenses. The company also granted…
